With a Darpin antiviral for treating Covid-19 Molecular Partners hopes to follow Vir’s regulatory path.
Medtronic’s quarterly results yesterday might presage a recovery, and some groups are in dire need of one.
And the move will shake up the orthopaedic robotics scene.
The company talks up sasanlimab, whose subcutaneous delivery might challenge at least some PD-(L)1 laggards.
As assurances that all is well fall on deaf ears, should Glaxosmithkline be thinking more radically?
The repeated failure of Roche’s ipatasertib increases the risk for Astrazeneca’s rival Akt inhibitor capivasertib.
Novo Nordisk is pushing Rybelsus into a pivotal Alzheimer’s trial despite the failure of the Elad study.
Big events for 2021 include the FDA’s decision on aducanumab and pivotal readouts in diabetes and autoimmunity, while investor enthusiasm will be closely monitored.
Though orthopaedics companies have begun to recover from the second quarter’s horrors, it is clear that the third quarter belongs to the diagnostics specialists.